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Summary 
From a selection of 25 antiviral compounds with specific anti-herpes activity or 
broad-spectrum antiviral properties, two compounds, namely (S)-9-(3-hydroxy-2- 
phosphonyl-methoxypropyl)adenine and 1-(2'-deoxy-2'-fluoro-13-D-arabinofura- 
nosyl)-5-iodouracil, appeared particularly effective in inhibiting the cytopathogen- 
icity of seal herpesvirus (phocid herpesvirus 1). 
Phocid herpesvirus 1; Seal herpesvirus; Antiviral compound 
Introduction 
Seal herpesvirus (SeHV) or phocid herpesvirus 1 is a highly pathogenic herpes- 
virus that has been recently isolated from the harbor seal (Phoca vitulina) during 
a lethal disease outbreak with symptoms of acute pneumonia nd focal hepatitis 
in a specialized seal orphanage in The Netherlands [20]. The severity of the dis- 
ease (about 50% mortality rate) and the isolation of SeHV as the causative agent 
of the disease have prompted the search for an effective antiviral chemotherapy. 
Therefore, various antiviral compounds were evaluated for their ability to inhibit 
SeHV infection in seal kidney (SeK) monolayer cell cultures. The compounds were 
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selected on the basis of their known antiherpetic potential (i.e. against herpes im- 
plex virus (HSV)) or broad-spectrum antiviral properties in general. 
Materials and Methods 
The compounds with the abbreviations used, their origin (source) and refer- 
ences to their synthesis and antiviral activity, are as follows: 
5-iodo-2'-deoxyuridine (IDU): Ludeco (Brussels, Belgium) [10]; 
5-trifluoro-2'-deoxythymidine (TFT): Sigma Chemical Company (St. Louis, MO, 
U.S.A.) [10]; 
5-ethyl-2'-deoxyuridine (EDU): courtesy of E. Mauz and B. Hempel, Robugen 
GmbH (Esslingen/Neckar, F.R. G) [ 10]; 
5-(2-chloroethyl)-2-'-deoxyuridine (CEDU): courtesy of B. Rosenwirth, Sandoz 
Forschungsinstitut (Vienna, Austria) [6,13]; 
(E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU): Rega Institute for Medical Re- 
search, University of Leuven (Leuven, Belgium) [7,10]; 
carbocyclic BVDU (C-BVDU): Rega Institute for Medical Research [8,14]; 
5-iodo-2'-deoxycytidine (IDC): Serva Feinbiochemica (Heidelberg, F.R.G) [10]; 
1-13-D-arabinofuranosylcytosine (Ara-C): The Upjohn Company (Puurs, Belgium) 
[10]; 
9-13-D-arabinofuranosyladenine (Ara-A): Parke Davis and Company (Ann Arbor, 
MI, U.S.A.) [10]; 
1-13-D-arabinofuranosylthymine (Ara-T): courtesy of H. Machida, Yamasa Shoyu 
Company (Choshi, Japan) [10]; 
1-13-D-arabinofuranosyl-(E)-5-(2-bromovinyl)uracil (BVaraU): courtesy of H. 
Machida [7]; 
1-(2'deoxy-2'-fluoro-13-D-arabinofuranosyl)-5-iodocytosine (FIAC): courtesy of J.J. 
Fox, Sloan-Kettering Institute (New York, NY, U.S.A,) [10,22]; 
1-(2'-deoxy-2'-fluoro-13-D-arabinofuranosyl)-5-iodouracil (FIAU): courtesy of J.J. 
Fox [22]; 
9-(2-hydroxyethoxymethyl)guanine (Acyclovir, ACV): Burroughs Wellcome 
Company (Research Triangle Park, NC, U.S.A.) [10]; 
9-[(1,3-dihydroxy-2-propoxy)methyl]guanine (DHPG, also referred to as NDG, 
BIOLF 62 and BW 759U): courtesy of J.P.H. Verheyden, Syntex Research (Palo 
Alto, CA, U.S.A.) [12,16]; 
The (R)- and (S)-enantiomers of 9-(3,4-dihydroxybutyl)guanine [(R)- and (S)- 
DHBG]: courtesy of B. Oberg, Astra L~ikemedel AB (S6dert~ilje, Sweden) [11]; 
phosphonoformate trisodium salt hexahydrate (PFA): Sigma Chemical Company 
[19]; 
ribavirin: ICN Nutritional Biochemicals (Cleveland, OH, U.S.A.) [21]; 
(S)-9-(2,3-dihydroxypropyl)adenine [(S)-DHPA]: courtesy of A. Hol~, Czechoslo- 
vak Academy of Sciences (Prague, Czechoslovakia) [9]; 
(RS)-3-adenin-9-yl-2-hydroxypropanoic cid [(RS)-AHPA] isobutyl ester: cour- 
tesy of A. Hol~ [4]; 
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carbocyclic 3-deazaadenosine (C-c3Ado): courtesy of J.A. Montgomery, Southern 
Research Institute (Birmingham, AL, U.S.A.) [5,18]; 
neplanocin A: courtesy of J. Murase, Toyo Jozo Company (Mifuku Ohito-Cho, 
Tagata-Gun, Shizuoka-Ken, Japan) [3]; 
9-(2-phosphonylmethoxyethyl)adenine (PMEA): courtesy of A. Hol~ [23]. 
(S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA]: courtesy of 
A. Hoi3~ [23]. 
Stock solutions of the test compounds were prepared at 1 mg/ml in tissue culture 
medium (F-10 maintenance medium, supplemented with 5% FCS, 100 IU/ml pen- 
icillin and 100 ixg/ml streptomycin). Stock solutions of the test compounds were 
diluted in tissue culture medium at 300, 100, 30, 10 ... 0.01 txg/ml. Of each dilution 
50 Ixl was mixed with 50 Ixl virus suspension, containing 100 TCIDs0 SeHV, and 
the mixtures (100 Ixl) were then added to confluent SeK cell cultures in microtiter 
plates. Per well 50 txl tissue culture medium was added, and the cells were further 
incubated for 65 h at 37°C. Viral cytopathogenicity was then recorded, and anti- 
viral activity was determined as the IC~0o, or lowest concentration f the test com- 
pound required to inhibit viral cytopathogenicity by 100%. Control cell cultures 
were incubated with serial dilutions of the test compounds, without virus, to detect 
possible cytotoxicity due to the test compounds. 
Cytotoxicity of the test compounds was monitored by measuring their inhibitory 
effect on the host cell DNA synthesis, based on a reduction in the incorporation 
of [methyl-3H]dThd. Therefore, the test compounds were diluted at 1 or 10 times 
their IC100 in tissue culture medium. To each dilution (50 I~1) 80000 SeK cells (100 
~1) and 0.5 ~Ci [methyl-3H]dThd (10 ~1) were added, and the mixtures were fur- 
ther incubated in microtiter plates for 24 h at 37°C. After freeze-thawing the amount 
of radioactivity incorporated into DNA was assessed, and the inhibition of DNA 
synthesis was expressed as a percentage r lative to the control (not exposed to the 
test compound). 
Results and Discussion 
Of the 25 compounds that were evaluated, only two compounds, namely (S)- 
HPMPA and FIAU, proved markedly inhibitory to SeHV. These compounds 
completely inhibited the cytopathogenicity of SeHV for SeK cells at a concentra- 
tion as low as 0.3 p~g/ml. (S)-HPMPA and FIAU could be considered as truly se- 
lective inhibitors of SeHV, as they were themselves not cytotoxic (based on a mi- 
croscopic evaluation of cell morphology) for the host cells at a concentration of
100 ~zg/ml; and, at a concentration 10times higher than the concentration required 
to completely suppress the cytopathic effect of SeHV, (S)-HPMPA and FIAU had 
only minor effect on host cell DNA synthesis: 15% and 23% reduction in [methyl- 
3H]dThd incorporation for (S)-HPMPA and FIAU, respectively (Table 1). 
It is noteworthy that those compounds that have been previously recognized as 
selective inhibitors of HSV replication, i.e. EDU, CEDU, BVDU, C-BVDU, IDC, 
Ara-T, BVaraU, FIAC, ACV and DHBG [6,7,8,10,11,12,13,14,16,22] were to- 
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tal ly inact ive against  SeHV.  On ly  those ant i -herpes  agents  that show litt le, if any,  
specif ic ity for  HSV,  i.e. IDU,  TFT ,  Ara -C ,  Ara -A ,  DHPG and PFA,  exh ib i ted  
some activity against SeHV but only at a fairly high concentrat ion (10 or 30 Ixl/ml). 
Moreover ,  IDU,  Ara -C ,  Ara -A  and PFA inh ib i ted host  cell  DNA synthesis  by 
about  50% at the  concent ra t ion  found  ef fect ive  against SeHV (Tab le  1), wh ich  in- 
d icates the lack of  select iv i ty  of  their  ant i -SeHV activity. 
Wi th  the broad-spect rum ant iv i ra l  agents,  r ibavir in,  (S ) -DHPA,  (RS) -AHPA,  
C -c3Ado and nep lanoc in  A ,  no marked  ant i -SeHV act iv ity was noted  (Tab le  1), 
which is perhaps not  surprising, since these compounds  are virtually inactive against 
herpesv i ruses  at large [3,4,5,9,18].  
The  mechan ism of  the  ant i -SeHV act ion of  (S ) -HPMPA and F IAU remains  to 
be  determined .  The  ant i -SeHV activity of (S ) -HPMPA and F IAU may be re la ted  
to their inhibitory activity against human cytomegalovi rus (HCMV) ,  since both (S)- 
HPMPA [23] and F IAU [2,15], are e f fect ive  inh ib i tors  of  HCMV repl icat ion,  But  
so is F IAC  [2,15], and F IAC was found ineffective against SeHV (Table 1). It would 
TABLE 1 
Inhibitory effects of selected antiviral compounds against SeHV in cell cultures 
Compound Anti-SeHV activity Cytotoxicity 
IC~ (~g/ml)* inhibition of DNA synthesis (%) 
at 1 ICt~ at 10 ICl~ 
IDU 10 56 82 
TFT 10 5 59 
EDU > 100 - - 
CEDU > 100 - 
BVDU > 100 - 
C-BVDU > l(10 - 
IDC > 100 - - 
Ara-C 30 7 l 95 
Ara-A 30 62 95 
Ara-T > 100 - - 
BVaraU > 100 - - 
FIAC l(10 - - 
FIAU 0.3 6 23 
ACV > 100 
DHPG 30 17 59 
(R)-DHBG > 100 
(S)-DHBG > l(/0 
PFA 30 43 55 
Ribavirin > 100 - - 
(S)-DHPA > 100 - - 
(RS)-AHPA > 100 - - 
C-c 3 Ado 30 74 76 
Neplanocin A 100 - - 
PMEA 30 29 74 
(S)-HPMPA 0.3 13 15 
* 100%-Inhibitory concentration, or concentration required to completely inhibit cytopathogenicity of 
100 TCIDso SeHV. Based on the incorporation of methyl-3H dThd into DNA uninfected SeK cells. 
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seem interest ing to examine how the other  2 ' - f luor inated compounds ,  i.e. FMAU,  
FEAU,  FMAC [2,15], behave in their  activity against SeHV.  
Thus, based on the present  data,  (S ) -HPMPA and F IAU would seem part icu- 
larly promis ing candidates for the t reatment  of the SeHV infection in seals, for 
which no effective therapy current ly exists. The ult imate usefulness of F IAU and 
(S ) -HPMPA will depend on their  therapeut ic  (toxicity/activity) ratio in vivo. The 
toxicity profi le of F IAU is rather  well establ ished [17]; that of (S ) -HPMPA is now 
under  investigation. In vivo studies in seals will be carr ied out when a new out- 
break  of SeHV infection takes place in the seal orphanage in The Nether lands.  
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